Gardiner Nancy B boosted its stake in Novartis AG (NYSE:NVS) by 15.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,065 shares of the company’s stock after buying an additional 2,545 shares during the period. Novartis AG makes up approximately 3.2% of Gardiner Nancy B’s investment portfolio, making the stock its 11th largest position. Gardiner Nancy B’s holdings in Novartis AG were worth $1,591,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Washington Trust Bank boosted its stake in Novartis AG by 0.3% in the second quarter. Washington Trust Bank now owns 4,384 shares of the company’s stock valued at $366,000 after buying an additional 14 shares in the last quarter. North Star Investment Management Corp. boosted its stake in Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after buying an additional 16 shares in the last quarter. Ledyard National Bank boosted its stake in Novartis AG by 0.9% in the second quarter. Ledyard National Bank now owns 3,428 shares of the company’s stock valued at $286,000 after buying an additional 30 shares in the last quarter. Kernodle & Katon Asset Management Group LLC boosted its stake in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares in the last quarter. Finally, First PREMIER Bank boosted its stake in Novartis AG by 2.4% in the first quarter. First PREMIER Bank now owns 2,242 shares of the company’s stock valued at $166,000 after buying an additional 52 shares in the last quarter. 11.27% of the stock is owned by institutional investors and hedge funds.

Novartis AG (NYSE:NVS) opened at 83.35 on Friday. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The company has a 50-day moving average of $84.17 and a 200-day moving average of $78.68. The company has a market cap of $195.28 billion, a price-to-earnings ratio of 30.43 and a beta of 0.73.

Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. Novartis AG’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. Equities research analysts expect that Novartis AG will post $4.73 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/novartis-ag-nysenvs-stake-raised-by-gardiner-nancy-b/1476515.html.

A number of research analysts have recently commented on NVS shares. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a report on Thursday, June 22nd. UBS AG reissued a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 30th. BidaskClub cut shares of Novartis AG from a “hold” rating to a “sell” rating in a report on Friday. Leerink Swann reissued a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. Finally, Vetr cut shares of Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 target price for the company. in a report on Tuesday, April 25th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $83.56.

In other news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The stock was bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.01% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.